NZ534231A - Use of acylaminoalkenylene-amide derivatives in treatment of functional motility disorders of the viscera - Google Patents

Use of acylaminoalkenylene-amide derivatives in treatment of functional motility disorders of the viscera

Info

Publication number
NZ534231A
NZ534231A NZ534231A NZ53423103A NZ534231A NZ 534231 A NZ534231 A NZ 534231A NZ 534231 A NZ534231 A NZ 534231A NZ 53423103 A NZ53423103 A NZ 53423103A NZ 534231 A NZ534231 A NZ 534231A
Authority
NZ
New Zealand
Prior art keywords
phenyl
hydrogen
methyl
formula
indol
Prior art date
Application number
NZ534231A
Other languages
English (en)
Inventor
John R Fozard
Eckhard Weber
Hans-Jurgen Pfannkuche
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NZ534231A publication Critical patent/NZ534231A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
NZ534231A 2002-02-08 2003-02-07 Use of acylaminoalkenylene-amide derivatives in treatment of functional motility disorders of the viscera NZ534231A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0203061.7A GB0203061D0 (en) 2002-02-08 2002-02-08 Organic compounds
PCT/EP2003/001227 WO2003066062A1 (en) 2002-02-08 2003-02-07 Use of acylaminoalkenylene-amide derivatives in functional motility disorders of the viscera

Publications (1)

Publication Number Publication Date
NZ534231A true NZ534231A (en) 2007-02-23

Family

ID=9930743

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ534231A NZ534231A (en) 2002-02-08 2003-02-07 Use of acylaminoalkenylene-amide derivatives in treatment of functional motility disorders of the viscera

Country Status (18)

Country Link
US (2) US20050203164A1 (cg-RX-API-DMAC10.html)
EP (2) EP1476167A1 (cg-RX-API-DMAC10.html)
JP (2) JP2005516994A (cg-RX-API-DMAC10.html)
KR (2) KR20040081492A (cg-RX-API-DMAC10.html)
CN (1) CN1301714C (cg-RX-API-DMAC10.html)
AU (1) AU2003244446B2 (cg-RX-API-DMAC10.html)
BR (1) BR0307479A (cg-RX-API-DMAC10.html)
CA (1) CA2471964A1 (cg-RX-API-DMAC10.html)
GB (1) GB0203061D0 (cg-RX-API-DMAC10.html)
IL (2) IL162816A0 (cg-RX-API-DMAC10.html)
MX (1) MXPA04007640A (cg-RX-API-DMAC10.html)
NO (1) NO20043735L (cg-RX-API-DMAC10.html)
NZ (1) NZ534231A (cg-RX-API-DMAC10.html)
PL (1) PL370255A1 (cg-RX-API-DMAC10.html)
RU (1) RU2353356C2 (cg-RX-API-DMAC10.html)
TW (1) TWI330177B (cg-RX-API-DMAC10.html)
WO (1) WO2003066062A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200404960B (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0203061D0 (en) * 2002-02-08 2002-03-27 Novartis Ag Organic compounds
AU2004283038B9 (en) * 2003-10-27 2008-04-24 Novartis Ag Use of neurokinin antagonists in the treatment of urinary incontinence
JP2010502736A (ja) 2006-09-08 2010-01-28 オレ・ファーマシューティカルズ・インコーポレーテッド 消化管の炎症を低減または軽減するための方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217996A (en) * 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
DE69602087T2 (de) * 1995-02-22 1999-09-09 Novartis Ag 1-aryl-2-acylamino-ethan-verbindungen und ihre verwendung als neurokinin- insbesondere als neurokinin-1-antagonisten
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
GB9525296D0 (en) * 1995-12-11 1996-02-07 Merck Sharp & Dohme Therapeutic agents
MY132550A (en) * 1996-08-22 2007-10-31 Novartis Ag Acylaminoalkenylene-amide derivatives as nk1 and nk2 antogonists
GB9708484D0 (en) * 1997-04-25 1997-06-18 Merck Sharp & Dohme Therapeutic agents
PL191496B1 (pl) * 1997-07-02 2006-05-31 Merck & Co Inc Odmiana polimorficzna 2-(R)-{1-(R) -[3,5-bis(trifluorometylo)-fenylo]etoksy} -3-(S)-(4-fluoro) fenylo-4-[3-(5-okso-1H,4H-1,2,4-triazolo)metylo] morfoliny, sposób jej wytwarzania, zawierająca ją kompozycja farmaceutyczna i jej zastosowanie
TW520370B (en) * 1998-11-20 2003-02-11 Meiji Seika Kaisha Benzooxazole derivatives and a pharmaceutical composition containing the derivatives as an active ingredient
RU2161894C1 (ru) * 1999-08-10 2001-01-20 НИФ "Ультрасан" Лечебно-профилактическая композиция
GB0010958D0 (en) 2000-05-05 2000-06-28 Novartis Ag Organic compounds
CA2432543A1 (en) * 2000-12-22 2002-07-04 Takeda Chemical Industries, Ltd. Combination drugs
GB0203061D0 (en) * 2002-02-08 2002-03-27 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
US20070293473A1 (en) 2007-12-20
JP2010241835A (ja) 2010-10-28
CA2471964A1 (en) 2003-08-14
BR0307479A (pt) 2004-12-07
KR20040081492A (ko) 2004-09-21
CN1301714C (zh) 2007-02-28
TW200302818A (en) 2003-08-16
HK1077749A1 (en) 2006-02-24
KR20100100994A (ko) 2010-09-15
IL162816A (en) 2010-11-30
US20050203164A1 (en) 2005-09-15
AU2003244446B2 (en) 2006-08-10
PL370255A1 (en) 2005-05-16
ZA200404960B (en) 2006-05-31
EP2216025A3 (en) 2010-11-10
IL162816A0 (en) 2005-11-20
AU2003244446A1 (en) 2003-09-02
EP1476167A1 (en) 2004-11-17
CN1627947A (zh) 2005-06-15
NO20043735L (no) 2004-09-07
JP2005516994A (ja) 2005-06-09
EP2216025A2 (en) 2010-08-11
MXPA04007640A (es) 2004-11-10
WO2003066062A1 (en) 2003-08-14
TWI330177B (en) 2010-09-11
RU2353356C2 (ru) 2009-04-27
RU2004127132A (ru) 2005-06-10
GB0203061D0 (en) 2002-03-27

Similar Documents

Publication Publication Date Title
EP3630101B1 (en) Tegavivint for use in the treatment of pulmonary fibrosis
SK25799A3 (en) Heterocyclic metalloprotease inhibitors
JP2002537332A (ja) 内臓痛を予防及び治療するためのガバペンチン誘導体
BR122018015003B1 (pt) kit compreendendo composições farmacêuticas de inibidor da nep e de valsartan ou seus sais
EP1415667B1 (en) Pancreatic juice secretion regulators comprising lpa receptor controller
US20070293473A1 (en) Use of acylaminoalkenylene-amide derivatives in functional motility disorders of the viscera
JPH11505243A (ja) Aii受容体アンタゴニストの新規な薬理学的使用
FR2896157A1 (fr) Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
HK1145139A (en) Use of acylaminoalkenylene-amide derivatives in irritable bowel syndrome and functional dyspepsia
JPH10511931A (ja) 非インシュリン依存性糖尿病の患者において胃空腹を抑制する1,5−ベンゾジアゼピン誘導体の使用
IE922378A1 (en) Antihypertensive combination
RU2700595C1 (ru) Производное 3,6,9-триазатрициклотетрадекана и его применение для лечения депрессии
JPH11246437A (ja) 消化管粘膜保護剤
JPH06234630A (ja) 中性メタロエンドペプチダーゼ阻害剤
AU2004283038B2 (en) Use of neurokinin antagonists in the treatment of urinary incontinence
HK1077749B (en) Use of acylaminoalkenylene-amide derivatives in functional motility disorders of the viscera
SU1375129A3 (ru) Способ получени новых тиокетеновых производных или их фармацевтически приемлемых солей
WO2004037266A1 (en) Compounds for the treatment of cough
WO2004063201A1 (ja) 統合失調症治療剤
JPH11286454A (ja) 虚血性脳血管障害の治療剤
JPS6013714A (ja) 胃腸細胞保護剤
JP2006503870A (ja) 睡眠障害の処置のための5−ht2受容体拮抗薬の使用
MX2008008894A (en) Combination of triazine derivatives and insulin secretion stimulators
WO2003015762A1 (en) Remedial agent for cardiac failure
JPH0867632A (ja) 中性メタロエンドペプチダーゼ阻害剤

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
LAPS Patent lapsed